Pyruvate dehydrogenase activation precedes the down-regulation of fatty acid oxidation in monocrotaline-induced myocardial toxicity in mice.


Journal

Heart and vessels
ISSN: 1615-2573
Titre abrégé: Heart Vessels
Pays: Japan
ID NLM: 8511258

Informations de publication

Date de publication:
Mar 2019
Historique:
received: 30 07 2018
accepted: 26 10 2018
pubmed: 6 11 2018
medline: 19 3 2019
entrez: 3 11 2018
Statut: ppublish

Résumé

Fatty acid (FA) oxidation is impaired and glycolysis is promoted in the damaged heart. However, the factor(s) in the early stages of myocardial metabolic impairment remain(s) unclear. C57B6 mice were subcutaneously administered monocrotaline (MCT) in doses of 0.3 mg/g body weight twice a week for 3 or 6 weeks. Right and left ventricles at 3 and 6 weeks after administration were subjected to capillary electrophoresis-mass spectrometry metabolomic analysis. We also examined mRNA and protein levels of key metabolic molecules. Although no evidence of PH and right ventricular failure was found in the MCT-administered mice by echocardiographic and histological analyzes, the expression levels of stress markers such as TNFα and IL-6 were increased in right and left ventricles even at 3 weeks, suggesting that there was myocardial damage. Metabolites in the tricarboxylic acid (TCA) cycle were decreased and those in glycolysis were increased at 6 weeks. The expression levels of FA oxidation-related factors were decreased at 6 weeks. The phosphorylation level of pyruvate dehydrogenase (PDH) was significantly decreased at 3 weeks. FA oxidation and the TCA cycle were down-regulated, whereas glycolysis was partially up-regulated by MCT-induced myocardial damage. PDH activation preceded these alterations, suggesting that PDH activation is one of the earliest events to compensate for a subtle metabolic impairment from myocardial damage.

Identifiants

pubmed: 30386918
doi: 10.1007/s00380-018-1293-3
pii: 10.1007/s00380-018-1293-3
doi:

Substances chimiques

Fatty Acids 0
Pyruvate Dehydrogenase Complex 0
pyruvate dehydrogenase activator 0
Monocrotaline 73077K8HYV

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

545-555

Références

J Card Fail. 2002 Dec;8(6):416-22
pubmed: 12528095
Cardiovasc Res. 2003 Jul 1;59(1):143-51
pubmed: 12829185
J Proteome Res. 2003 Sep-Oct;2(5):488-94
pubmed: 14582645
Toxicol Sci. 2004 Jan;77(1):172-82
pubmed: 14600277
J Physiol. 2004 Feb 15;555(Pt 1):1-13
pubmed: 14660709
Cardiovasc Res. 2005 Jun 1;66(3):454-61
pubmed: 15914110
Physiol Rev. 2005 Jul;85(3):1093-129
pubmed: 15987803
J Biol Chem. 2006 Jun 16;281(24):16768-76
pubmed: 16608839
J Appl Physiol (1985). 2007 Jul;103(1):287-95
pubmed: 17412785
Circulation. 2007 Jul 24;116(4):434-48
pubmed: 17646594
Am J Physiol Heart Circ Physiol. 2009 Aug;297(2):H576-82
pubmed: 19502553
J Pharmacol Sci. 2009 Sep;111(1):33-43
pubmed: 19763046
J Mol Med (Berl). 2010 Jan;88(1):47-60
pubmed: 19949938
J Cardiovasc Pharmacol. 2010 Aug;56(2):130-40
pubmed: 20505524
J Hypertens. 2011 Feb;29(2):299-308
pubmed: 21063214
Circulation. 2011 Jun 7;123(22):2552-61
pubmed: 21606392
J Mol Med (Berl). 2012 Jan;90(1):31-43
pubmed: 21874543
Am J Physiol Lung Cell Mol Physiol. 2012 Feb 15;302(4):L363-9
pubmed: 21964406
Am J Physiol Heart Circ Physiol. 2012 Apr 15;302(8):H1655-66
pubmed: 22245771
J Surg Oncol. 2012 Jul 1;106(1):72-8
pubmed: 22287334
Am J Physiol Lung Cell Mol Physiol. 2012 May 15;302(10):L977-91
pubmed: 22307907
Cardiol Clin. 2012 May;30(2):257-69
pubmed: 22548816
Circ Heart Fail. 2012 Jul 1;5(4):493-503
pubmed: 22705769
Circ Res. 2012 Aug 17;111(5):628-41
pubmed: 22904042
Biochim Biophys Acta. 2013 Apr;1833(4):857-65
pubmed: 22960640
Am J Physiol Heart Circ Physiol. 2013 Aug 15;305(4):H494-505
pubmed: 23792677
Circ Res. 2013 Aug 30;113(6):709-24
pubmed: 23989714
Am J Physiol Heart Circ Physiol. 2015 Nov;309(9):H1453-67
pubmed: 26386112
Biomed Environ Mass Spectrom. 1988 Mar 1;15(5):265-73
pubmed: 3365497
Cancer Res. 1984 Apr;44(4):1505-9
pubmed: 6423276

Auteurs

Gaku Nakai (G)

Department of Life Science and Medical Bioscience, Waseda University, Tokyo, Japan.

Daisuke Shimura (D)

Department of Life Science and Medical Bioscience, Waseda University, Tokyo, Japan.

Ken Uesugi (K)

Department of Life Science and Medical Bioscience, Waseda University, Tokyo, Japan.

Ichige Kajimura (I)

Department of Cell Physiology, The Jikei University School of Medicine, 3-25-8 Nishishinbashi, Minatoku, Tokyo, 105-8461, Japan.

Qibin Jiao (Q)

Department of Cell Physiology, The Jikei University School of Medicine, 3-25-8 Nishishinbashi, Minatoku, Tokyo, 105-8461, Japan.
Department of Cardiology, The Affiliated Hospital of Hangzhou Normal University, Hangzhou, China.

Yoichiro Kusakari (Y)

Department of Cell Physiology, The Jikei University School of Medicine, 3-25-8 Nishishinbashi, Minatoku, Tokyo, 105-8461, Japan.

Tomoyoshi Soga (T)

Institute for Advanced Biosciences, Keio University, Yamagata, Japan.

Nobuhito Goda (N)

Department of Life Science and Medical Bioscience, Waseda University, Tokyo, Japan.

Susumu Minamisawa (S)

Department of Life Science and Medical Bioscience, Waseda University, Tokyo, Japan. sminamis@jikei.ac.jp.
Department of Cell Physiology, The Jikei University School of Medicine, 3-25-8 Nishishinbashi, Minatoku, Tokyo, 105-8461, Japan. sminamis@jikei.ac.jp.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH